Roche Holding AG said Thursday that John Reed, head of pharma research and early development, has decided to leave the company and will be replaced by William Pao.
Mr. Pao is currently global head of the oncology discovery and translational area at the research and development department and will assume his new role on April 2, Roche said. He will also become a member of the company’s enlarged corporate executive committee.
“Since joining Roche in 2014, William has been instrumental in the build-up of cancer immunotherapy and molecular targeted therapies,” said Chief Executive Severin Schwan, on the appointment.
By Alberto Declaux
Echosens, a high-technology company offering liver diagnostic solutions, and Novo Nordisk A/S, a leading global healthcare company, announced a partnership to advance early diagnosis of non-alcoholic steatohepatitis (NASH) and increase awareness of the disease among patients, healthcare providers and other stakeholders.
Positive opinion based on Phase 3 ADAPT trial showing efgartigimod provided clinically meaningful improvements in strength and quality of life measures. If approved, efgartigimod will be the first neonatal Fc receptor (FcRn) blocker for the treatment of adults in Europe living with rare neuromuscular disease generalized myasthenia gravis (gMG).
Galapagos CEO Paul Stoffels, M.D., has finally taken the plunge on M&A. The newly minted chief executive has signed not one but two deals in an attempt to right the ship, bringing two small biotechs aboard for a combined 239 million euros ($251.4 million).